Latest News Archive

Please select Category, Year, and then Month to display items
Years
2019 2020 2021
Previous Archive
05 June 2019 | Story Leonie Bolleurs | Photo Leonie Bolleurs
Lucas Erasmus and Prof Hendrik Swart
Lucas Erasmus and Prof Hendrik Swart (right) are working on a joint project with Ghent University to find an attractive solution to address the energy demands of buildings, electric motor vehicles, and mobile electronics.

With a constant increase in the price of electricity, any innovation to replace this necessity in our daily lives is welcome. 

The University of the Free State (UFS), whose vision is supported by an element of innovation, welcomes the recent agreement between its Department of Physics and Ghent University.

Attractive solution


Not only will this research – which aims to develop the materials necessary for transparent solar panels – enlarge the international research footprint of the UFS, but it is also an attractive solution to address the energy demands of buildings, electric motor vehicles, and mobile electronics without affecting their appearance.

According to Prof Hendrik Swart, from the UFS Department of Physics, the agreement between the two universities entails a joint doctoral degree in which both universities will supervise the project and the awarding of the doctorate. The student, Lucas Erasmus, will conduct research at both institutions.

Transparent solar panel

The idea with the research is to develop glass that is transparent to visible light, just like the glass you find in the windows of buildings, motor vehicles, and mobile electronic devices. However, by incorporating the right phosphor materials inside the glass, the light from the sun that is invisible to the human eye (ultraviolet and infrared light) can be collected, converted, and concentrated to the sides of the glass panel where solar panels can be mounted. This invisible light can then be used to generate electricity to power these buildings, vehicles, and electronic devices. The invention is therefore a type of transparent solar panel.

Implemented in cellphone screens

This technology can be implemented in the building environment to meet the energy demands of the people inside the buildings. 

The technology is also good news for the 4,7 billion cellphone users in the world, as it can be implemented in the screens of cellphones, where the sun or the ambient light of a room can be used to power the device without affecting its appearance. 

Another possible application is in electric cars, where the windows can be used to help power the vehicle.

Low-income housing

Erasmus added: “We are also looking at implementing this idea into hard, durable plastics that can act as a replacement for zinc roofs.” 

“This will allow visible light to enter housing, and the invisible light can then be used to generate electricity. The device also concentrates the light from a large area to the small area on the sides where the solar panels are placed; therefore, reducing the number of solar panels needed and, in return, reducing the cost.”

The technology will take about a decade to implement.

“This study is currently ongoing, and we are experimenting and testing different materials in order to optimise the device in the laboratory. After this, it needs to be upscaled in order to test it in the field. It is truly the technology of the future,” said Erasmus.

Video: Barend Nagel

News Archive

UFS to monitor the use of ARV-drugs on pregnant women and children
2004-12-08

The University of the Free State (UFS) is to establish a Pharmacovigilance Centre that will monitor the effects of Anti-Retroviral (ARV) drugs on HIV positive pregnant women and children starting early in the new year.

The UFS is one of only two institutions chosen by the Minister of Health, Dr Manto Tshabalala-Msimang, to establish such an ARV monitoring centre.

The other centre will be based at Medical University of South Africa (MEDUNSA) and will concentrate mainly on monitoring the effects of the drugs on adults.

“The establishment of the UFS’s Pharmaconvigilance Centre forms part of government’s Comprehensive Plan on HIV and AIDS, often termed the roll-out plan for ARV drugs. The centre’s primary responsibility will be to specifically monitor the use of these drugs in pregnant women, and children under the age of 13,” said Prof Andrew Walubo of the UFS’s Department of Pharmacology.

“Although most of the side effects of ARV drugs have been identified in other countries, it has now become critical to identify the side effects amongst the South African population. This is important because many people will be exposed to the drugs within a short time. Our aim is so identify the most common side effects and make recommendations for the prevention thereof. The centre will help in detecting the risk of using anti-retroviral drugs in pregnancy and children, and prevention of adverse drug reactions,” said Prof Walubo.

According to Prof Walubo 12 drugs will be monitored – these drugs will be selected according to the patient’s profile.

The centre will comprise of two components: A pregnancy registry, which will focus on a new-born child up until two months and a pediatric registry, which will focus on children who are born of mothers who used ARV drugs and children using ARV drugs.

According to Prof Walubo, the Pharmaconvigilance Centre will also be responsible for offering relevant technical advice, training and selected research on ARV drugs in these patients.

The centre will be fully sponsored by the national Department of Health. It will be based in the UFS’s Faculty of Health Sciences, Department of Pharmacology, and will be run in collaboration with experts from different departments in the faculty.

Media release
Issued by: Lacea Loader
Media Representative
Tel: (051) 401-2584
Cell: 083 645 2454
E-mail: loaderl.stg@mail.uovs.ac.za
8 December 2004

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept